Circulating anti-citrullinated peptide antibodies, cytokines and genotype as biomarkers of response to disease-modifying antirheumatic drug therapy in early rheumatoid arthritis

BACKGROUND: To measure circulating anti-citrullinated peptide antibodies (ACPA) and cytokines pre- and 6 months post-therapy as a strategy to predict and optimize responses to traditional disease-modifying antirheumatic drugs (DMARDs) in early RA, which is an unmet need in developing countries. PATI...

Descripción completa

Detalles Bibliográficos
Autores principales: Ally, Mahmood M. T. M., Hodkinson, Bridget, Meyer, Pieter W. A., Musenge, Eustasius, Tintinger, Gregory R., Tikly, Mohammed, Anderson, Ronald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4446850/
https://www.ncbi.nlm.nih.gov/pubmed/26021985
http://dx.doi.org/10.1186/s12891-015-0587-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4446850/
https://www.ncbi.nlm.nih.gov/pubmed/26021985
http://dx.doi.org/10.1186/s12891-015-0587-1

Ejemplares similares